Received Oct 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLUN3 | INFLUENZA (SEASONAL) (FLUMIST) | MEDIMMUNE VACCINES, INC. | UNK | — | — |
PYREXIA, DYSAESTHESIA, VOMITING, DECREASED APPETITE, NASAL CONGESTION, NASAL POLYPS; dysaesthesia; vomiting; decreased appetite; nasal congestion; nasal polyps; A spontaneous report has been received from a consumer. The report concerns a female patient (age not provided). No medical history was reported. No concomitant products were reported. The patient received Flumist, via unknown on an unknown date. The patient received 1 dose(s). It was unknown who administered Flumist to the patient. On an unknown date, the patient experienced pyrexia, dysaesthesia, vomiting, decreased appetite, nasal congestion, nasal polyps (preferred term: Pyrexia), nasal polyps (preferred term: Nasal polyps), nasal congestion (preferred term: Nasal congestion), decreased appetite (preferred term: Decreased appetite), vomiting (preferred term: Vomiting) and dysaesthesia (preferred term: Dysaesthesia). The outcome of the event(s) of decreased appetite, dysaesthesia, nasal congestion, nasal polyps, pyrexia, dysaesthesia, vomiting, decreased appetite, nasal congestion, nasal polyps and vomiting was unknown. The events were considered non-serious. Device Information: Combination Product Report: Yes Product As Reported: Flumist Brand Name: FLUMIST Product Role: Suspect Manufacturer Name: ASTRAZENECA Labeled for single use: No Corrected report on 18-Oct-2025: data fields County, email and Vaccine Facility Information set as NF. Narrative amended. Case corrected as a result of MCQC. Non-Significant correction on 20-Oct-2025: Vaccine facility state field updated. Narrative amended. Non-Significant correction on 21-Oct-2025: Nullflavor removed for telephone and fax, Narrative amended.